The value of FDG-PET/CT metabolic parameters and treatment metabolic response in predicting long-term survival of patients with diffuse large B-cell lymphoma
Novelty in Biomedicine,
Vol. 13 No. 1 (2025),
20 Bahman 2025
,
Page 1-9
https://doi.org/10.22037/nbm.v13i1.45530
Abstract
Background: Few trials have been conducted regarding using PET/CT metabolic parameters as a predictor for the long-term survival of patients with lymphoma. The present study aimed to determine the prognostic value of quantitative metabolic parameters based on FDG-PET/CT in predicting 2-year mortality and disease recurrence in patients with diffuse large B-cell lymphoma (DLBCL).
Materials and Methods: This cross-sectional study was performed on patients who suffered DLBCL and assessed by FDG-PET/CT. All patients have been scheduled for first-line therapy, including the R-CHOP regimen (Rituximab, Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone). The records of patients eligible for the study were extracted from the hospital archive. All subjects were followed up for 2 years to assess progression-free survival (PFS) and overall survival (OS).
Results: Complete response to treatment was revealed in 80.0%, while the disease was progressive in 5.7% and stable in 2.9%. At the end of 2 years of follow-up, in all groups, five people (14.2%) experienced disease relapse, and one person (2.9%) died. Comparing metabolic parameters of PET/CT between survived and non-survived groups showed no difference between the two groups. Similarly, the median value of pointed metabolic parameters was insignificant between groups with and without disease relapse. The comparison of the treatment metabolic response state between non-survived and survived subgroups showed no difference. However, regarding the metabolic response status according to the presence or lack of recurrence, those with disease recurrence experienced a higher rate of progressive metabolic disease condition. Treatment metabolic non-response status and higher Deauville 5-point score (D5PS) score could effectively differentiate the groups with and without disease recurrence.
Conclusion: FDG-PET/CT complete metabolic response can predict longer PFS in patients with DLBCL, but its related metabolic parameters may not predict disease outcome.
- Diffuse large B-cell lymphoma
- MTV
- TLG
- FDG PET/CT
- Prognosis
How to Cite
References
Nastoupil LJ, Bartlett NL. Navigating the Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2023;41(4):903-913.
Wang L, Li LR, Young KH. New agents and regimens for diffuse large B cell lymphoma. J Hematol Oncol. 2020;13(1):175.
Poletto S, Novo M, Paruzzo L, Frascione PMM, Vitolo U. Treatment strategies for patients with diffuse large B-cell lymphoma. Cancer Treat Rev. 2022 Nov;110:102443.
Kostakoglu L, Nowakowski GS. End-of-Treatment PET/Computed Tomography Response in Diffuse Large B-Cell Lymphoma. PET Clin. 2019;14(3):307-315.
Kobe C, Dietlein M, Hellwig D. PET/CT for Lymphoma Post-therapy Response Assessment in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma. Semin Nucl Med. 2018;48(1):28-36.
Ferrández MC, Golla SSV, Eertink JJ, de Vries BM, Lugtenburg PJ, Wiegers SE, Zwezerijnen GJC, Pieplenbosch S, Kurch L, Hüttmann A, Hanoun C, Dührsen U, de Vet HCW; PETRA; Zijlstra JM, Boellaard R. An artificial intelligence method using FDG PET to predict treatment outcome in diffuse large B cell lymphoma patients. Sci Rep. 2023;13(1):13111.
Eertink JJ, Zwezerijnen GJC, Heymans MW, Pieplenbosch S, Wiegers SE, Dührsen U, Hüttmann A, Kurch L, Hanoun C, Lugtenburg PJ, Barrington SF, Mikhaeel NG, Ceriani L, Zucca E, Czibor S, Györke T, Chamuleau MED, Hoekstra OS, de Vet HCW, Boellaard R, Zijlstra JM. Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma. Blood. 2023;141(25):3055-3064.
PET/CT for Lymphoma Post-therapy Response Assessment in Kobe C, Dietlein M, Hellwig D. Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma. Semin Nucl Med. 2018;48(1):28-36.
Kostakoglu L, Martelli M, Sehn LH, Belada D, Carella AM, Chua N, Gonzalez-Barca E, Hong X, Pinto A, Shi Y, Tatsumi Y, Knapp A, Mattiello F, Nielsen T, Sahin D, Sellam G, Oestergaard MZ, Vitolo U, Trněný M. End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA. Blood Adv. 2021;5(5):1283-1290
Susanna Tokola, Hanne Kuitunen. Interim and end-of-treatment PET-CT suffers from high false-positive rates in DLBCL: Biopsy is needed prior to treatment decisions. Cancer Med 2021;10(9):3035-3044.
Zhu L, Meng Y, Guo L, Zhao H, Shi Y, Li S, Wang A, Zhang X, Shi J, Zhu J, Xu K. Predictive value of baseline (18)F-FDG PET/CT and interim treatment response for the prognosis of patients with diffuse large B-cell lymphoma receiving R-CHOP chemotherapy. Oncol Lett. 2021;21(2):132.
Adams HJ, Kwee TC. Prognostic value of interim FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: Systematic review and meta-analysis. Crit Rev Oncol Hematol. 2016 Oct;106:55-63.
Manohar K, Mittal BR, Bhattacharya A, Malhotra P, Varma S. Fluoro-deoxy-glucose positron emission tomography/computed tomography in lymphoma: A pictorial essay. Indian J Nucl Med. 2013;28(2):85-92.
Kim HJ, Lee R, Choi H, Paeng JC, Cheon GJ, Lee DS, Chung JK, Kang KW. Application of Quantitative Indexes of FDG PET to Treatment Response Evaluation in Indolent Lymphoma. Nucl Med Mol Imaging. 2018;52(5):342-349.
Aatif Parvez 1, Noam Tau. 18F-FDG PET/CT metabolic tumor parameters and radiomics features in aggressive non-Hodgkin's lymphoma as predictors of treatment outcome and survival. Ann Nucl Med. 2018;32(6):410-416
Song YQ, Zhu J. Clinical values of 18F-FDG PET in lymphoma. Zhonghua Yi Xue Za Zhi. 2012;92(46):3241-2.
- Abstract Viewed: 128 times
- pdf Downloaded: 95 times